The Cystine Glutamate Antiporter And Classical Glutamate Transporters In Normal And Pathological Brains And Retinae
Funder
National Health and Medical Research Council
Funding Amount
$416,000.00
Summary
This project will examine the role of a system that transports a toxic neurotransmitter, glutamate out of cells where it is relatively harmless, into the space surrounding nerve cells where it can be highly toxic. Previous models for the aberrant release of glutamate under pathological conditions such as strokes, have relied on the notion that other specialised glutamate transporters which normally work to remove glutamate from the space surrounding nerve cells, actually reverse their direction ....This project will examine the role of a system that transports a toxic neurotransmitter, glutamate out of cells where it is relatively harmless, into the space surrounding nerve cells where it can be highly toxic. Previous models for the aberrant release of glutamate under pathological conditions such as strokes, have relied on the notion that other specialised glutamate transporters which normally work to remove glutamate from the space surrounding nerve cells, actually reverse their direction of action and release glutamate. The current study investigates a transport system (called the cystine-glutamate antiporter) where the normal direction of action is to release glutamate. This system has been overlooked despite evidence that it could be involved in releasing glutamate and thus contribute to the death of nerve cells in a variety of human pathologies including glaucoma of the eye, epilepsy, and brain damage that occurs when the blood supply to the brain is interrupted, such as after a heart attack. This study examines both human tissues and animal models of disease states to determine if similar transport systems are present and if the cystine-glutamate antiporter might contribute to human nervous diseases. The function and distribution of the cystine-glutamate antiporter will be compared with classical transporters, under normal and pathological conditions, including situations where we have shown that it is possible to experimentally perturb normal glutamate transporter expression.Read moreRead less
Functional Characterisation Of A New Regulatory Mechanism For CaMKII At Synapses In Vivo
Funder
National Health and Medical Research Council
Funding Amount
$547,315.00
Summary
CaMKII is an important regulatory molecule in the brain where it plays an essential role in certain forms of learning and memory and in the appropriate development and maturation of neural pathways and undergoes specific changes in animal models of brain ischaemia and epilepsy. Recent evidence has shown that, in nerve cells, the regulation and role of CaMKII is more complicated than previously thought. This project will investigate the roles of a new control mechanism in regulating the function ....CaMKII is an important regulatory molecule in the brain where it plays an essential role in certain forms of learning and memory and in the appropriate development and maturation of neural pathways and undergoes specific changes in animal models of brain ischaemia and epilepsy. Recent evidence has shown that, in nerve cells, the regulation and role of CaMKII is more complicated than previously thought. This project will investigate the roles of a new control mechanism in regulating the function of CaMKII in nerve cells. The experiments will involve an international team of collaborators using cutting edge techniques at the molecular, cellular and whole animal level. This will provide a more complete understanding of how CaMKII influences brain function and allow an assessment of whether CaMKII regulation might be a suitable target for drugs aimed at protecting against the damaging effects of brain injury following stroke or heart attack.Read moreRead less